Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05420012 · ClinicalTrials.gov registry record · Phase 4
The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation
A Phase 4 study of Heart Failure and Heart Failure With Reduced Ejection Fraction (HFrEF), sponsored by Josef Stehlik.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
- 2
- Study locations
NCT05420012 is a Phase 4 study of Heart Failure and Heart Failure With Reduced Ejection Fraction (HFrEF) that has completed, run by Josef Stehlik. The registered enrollment target is 26 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05420012, a Phase 4 study of Heart Failure and Heart Failure With Reduced Ejection Fraction (HFrEF), has completed, sponsored by Josef Stehlik.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
- 2
- Study locations
Study Summary
The concept that direct stimulation of soluble guanylate cyclase (sGC) could be a particularly effective approach to increase cyclic guanosine monophosphate (cGMP) in conditions of increased inflammation/oxidative stress, endothelial dysfunction, and reduced nitric oxide (NO) bioavailability. Thus, the aim of the proposed study is to examine the effect of Vericiguat on peripheral vascular function, inflammatory status, and patient health status. The study also aims to identify patients who are particularly likely to benefit from Vericiguat treatment and predict that these patients will be defined by baseline peripheral vascular dysfunction and high inflammatory state.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vericiguat
Study Locations (2)
Utah
- University of Utah Hospital - Salt Lake City
- Veterans Affairs Salt Lake City Health Care System (VAMC) - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2024-10-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05420012
The ClinicalTrials.gov registry entry for NCT05420012 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The listed sponsor is Josef Stehlik, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05420012 reports 2 study locations spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT05420012 about?
NCT05420012 is a clinical study titled "The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation". The concept that direct stimulation of soluble guanylate cyclase (sGC) could be a particularly effective approach to increase cyclic guanosine monophosphate (cGMP) in conditions of increased inflammation/oxidative stress, endothelial dysfunction, and reduced nitric oxide (NO) bioavailability. Thus, ...
What is the current status of trial NCT05420012?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2023-05-01. Estimated completion is 2024-10-24.
What conditions does trial NCT05420012 study?
This clinical trial studies the following conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF).
What interventions are being tested in trial NCT05420012?
The interventions under investigation include: Placebo (DRUG), Vericiguat (DRUG).
Who is sponsoring clinical trial NCT05420012?
This trial is sponsored by Josef Stehlik, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05420012 being conducted?
This trial has 2 study locations across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure
RECRUITING · Phase 4
-
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
RECRUITING · Phase 4
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
The STOP-MED CTRCD Trial
RECRUITING · Phase 4
-
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
RECRUITING · Phase 4
-
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.